Is Genpact’s AI-First Leadership Overhaul Reshaping the Investment Case For Genpact (G)?

• Earlier in December 2025, Genpact expanded its executive team, appointing leaders for corporate development, NextGen Enterprises, and the legal function to advance its GenpactNext, AI-first strategy.
• By bringing in senior talent from IBM, NTT Data, Accenture, and major tech firms, Genpact is explicitly reinforcing its shift toward Agentic and advanced technology solutions built on differentiated, “last mile” execution capabilities.
• Next, we’ll examine how this leadership expansion, especially the new Head of Corporate Development, may reshape Genpact’s existing investment narrative.

AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Genpact Investment Narrative Recap

To own Genpact, you need to believe its pivot from slower growing legacy BPO into higher value Data Tech AI and digital operations can offset decelerating Core Business Services and a muted demand backdrop. The latest executive hires appear directionally supportive of this AI first push, but do not materially change the near term catalyst of Advanced Technology Solutions adoption or the key risk that rising competition and self funded AI investment could pressure margins if ramp up is slower than expected.

Among recent developments, Genpact’s consistent quarterly dividend of US$0.17 per share in 2025 stands out, as it underlines the company’s ongoing capital return while it reinvests heavily in AI capabilities and talent. For investors, this combination of cash returns and reinvestment sits alongside the main catalyst of growing demand for higher margin, annuitized AI rich solutions and the risk that legacy revenue softness or delayed large deal signings could weigh on the pace of any earnings improvement.

Yet while the AI centric growth story is appealing, investors should also be aware of the rising competitive intensity and what it could mean for...

Read the full narrative on Genpact (it's free!)

Genpact's narrative projects $5.9 billion revenue and $669.6 million earnings by 2028.

Uncover how Genpact's forecasts yield a $50.20 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community currently span roughly US$33.84 to about US$78.18, showing how far apart individual views on Genpact can be. When you set that against the core catalyst of faster adoption of higher margin Advanced Technology Solutions, it underlines why taking in multiple perspectives can be useful before forming an opinion on the company’s prospects.

Explore 3 other fair value estimates on Genpact - why the stock might be worth as much as 63% more than the current price!

Build Your Own Genpact Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Genpact research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Genpact research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Genpact's overall financial health at a glance.

No Opportunity In Genpact?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com